Twist Bioscience Corporation (TWST) drops after deep earnings miss
Twist Bioscience Corporation (TWST) drops despite revenue growth and raised guidance, as a wider-than-expected EPS loss overshadowed strong segment momentum, margin improvement, and continued sequential sales gains. This deep-dive breaks down the earnings miss, operating trends, and why investors focused on profitability over the top-line beat.
Twist Bioscience Corporation (TWST) dropped after reporting a wider-than-expected quarterly loss, with EPS of -$0.71 versus the -$0.54 estimate. Revenue rose 19.3% year over year to $110.7 million, and management lifted full-year revenue guidance, signaling that the business is still scaling even as profitability remains the market’s main concern. Investors should view the quarter as operationally constructive but financially uneven, with growth intact and earnings still lagging expectations.
Twist Bioscience Corporation (TWST) drops after its latest quarterly report, even though revenue rose and management lifted full-year guidance. The headline problem was earnings: TWST posted EPS of -$0.71 versus the -$0.54 estimate, and that miss kept the market focused on profitability instead of top-line momentum.
Shares closed at $56.19, down 6.97%, on volume of 2,575,036 shares versus an average of 1,284,763. That price action tells the story in plain English: investors liked the growth narrative, but they did not ignore the wider-than-expected loss.
Key Takeaways
TWST earnings missed on EPS, with actual EPS of -$0.71 versus the -$0.54 estimate, while revenue came in at $110.7M, roughly in line with the $110M estimate.
The strongest operating area was DNA synthesis and protein solutions, which grew 28% YoY to $53.3M, while NGS applications rose 12% YoY to $57.4M and 9% sequentially.
Management raised FY2026 revenue guidance to $442M to $447M and reiterated its goal of adjusted EBITDA breakeven in Q4 FY2026.
CEO Emily Leproust framed the quarter around scale and share gains, pointing to a 13th straight quarter of sequential revenue growth and strength tied to AI-enabled drug discovery.
Gross margin reached 51.6%, and adjusted EBITDA loss improved by $1.5M from the prior-year quarter to -$13.3M, showing operating progress despite the EPS miss.
Analyst reaction leaned constructive. TD Cowen kept its Buy rating and raised its price target to $68 from $58 after the report, citing revenue strength and improved guidance.
Financial Performance Breakdown
Twist Bioscience Corporation earnings analysis starts with a split result. Revenue held up well, but EPS missed by a wide margin. TWST reported Q2 FY2026 revenue of $110.7M, up 19.3% YoY, while EPS came in at -$0.71. Consensus called for -$0.54, so the loss was materially worse than expected even as revenue matched the Street near $110M.
On a sequential basis, the company kept its growth streak alive. CEO Emily Leproust said Twist posted its 13th quarter of sequential revenue growth. That matters because the company is trying to prove it can scale consistently across a choppy life sciences tools backdrop.
Twist delivered another strong quarter and extended our track record of consistent execution, posting our 13th quarter of sequential revenue growth. — Emily Leproust, CEO
Segment performance was solid and fairly balanced. DNA synthesis and protein solutions generated $53.3M, up 28% YoY. NGS applications produced $57.4M, up 12% YoY and 9% sequentially. Within end markets, therapeutics revenue reached $40.8M, up 55% YoY, while diagnostics revenue hit $40.0M, up 14% YoY and 13% sequentially.
That mix matters. DNA synthesis and protein solutions delivered the faster growth rate, and management tied that strength to AI-enabled drug discovery work. NGS, meanwhile, reaccelerated and remained a durable revenue base, especially in oncology diagnostics and MRD workflows. In other words, one side of the business is sprinting while the other is still moving with purpose. That is a healthier setup than a one-engine story.
Margins also moved in the right direction. Gross margin was 51.6%, which supports management's argument that Twist's silicon-based DNA platform is creating operating leverage as volume grows. Adjusted EBITDA loss was -$13.3M, an improvement of $1.5M from the prior-year quarter. Net income on the quarterly financial snapshot was -$0.04B for the March 31, 2026 quarter, compared with -$0.03B in the prior two quarters and -$0.04B in the year-ago March quarter.
EPS history shows why the market stayed cautious. TWST posted EPS of -$0.71 in the latest quarter, versus -$0.50 in the prior quarter, -$0.45 in the quarter before that, and -$0.66 in the year-ago period. So while revenue keeps climbing, bottom-line volatility has not gone away. For growth investors, that is manageable. For a market that now demands cleaner paths to profitability, it is a friction point.
The balance sheet still gives Twist room to execute. Cash and short-term investments stood at $171.7M at quarter-end. That cash position matters because management is still investing in platform expansion, new product introductions, and commercial programs tied to AI drug discovery and oncology diagnostics.
Market Reaction and Analyst Response
The immediate stock reaction was negative. TWST closed at $56.19, down 6.97%, and trading volume ran at roughly 2x average daily volume. That kind of move usually means the market found one issue impossible to ignore. Here, it was the EPS miss.
Yet the analyst response was more constructive than the stock chart. TD Cowen raised its price target to $68 from $58 and maintained a Buy rating after the quarter. The firm pointed to revenue of about $111M, up 19% YoY, plus strength in both major segments. That is a notable divergence: the market marked the stock down, while at least one major firm marked its valuation up.
That split is not unusual for a company like Twist. The stock often trades on two clocks at once. The short-term clock reacts to EPS misses and risk appetite. The longer-term clock reacts to revenue durability, margin progress, and whether the platform is taking share. On those longer-cycle metrics, the quarter gave bulls real material to work with.
Street positioning was already broadly positive. Analyst consensus stood at Buy, with 10 Buy ratings, 2 Holds, and 1 Sell. Before the report, some analysts had been constructive but alert to valuation after a strong run. The post-earnings target increase from TD Cowen shows that at least part of the Street believes the raised guidance and segment growth justify a higher view, even after the earnings miss.
There was also useful context from Guggenheim before the print. On April 15, 2026, Guggenheim reiterated Buy and a $55 target after Amazon launched Amazon BioDiscovery and highlighted Twist as a wet lab partner. That call now looks more relevant because management used the quarter to connect the AWS relationship to real commercial momentum in AI-enabled discovery.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The TWST earnings call centered on one strategic message: Twist believes its silicon-based DNA synthesis platform is widening the gap on cost, speed, and scale. CEO Emily Leproust leaned hard into that argument and tied it directly to market share gains, product breadth, and the rise of AI-driven drug discovery.
The model works exactly as designed. We have delivered sustained revenue growth, expanded margin above 50%, invested strategically to drive continued return on that investment, and we remain firmly on track to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. — Emily Leproust, CEO
That quote matters because it links three things investors care about: growth, margin, and breakeven timing. Leproust also gave the clearest strategic read on what is driving demand. She said Twist identified AI-enabled discovery early and invested ahead of the market. Then she backed that claim with a named commercial relationship.
Last month, Amazon Web Services announced Twist as a wet lab partner for Amazon BioDiscovery, its AI-powered drug discovery application. — Emily Leproust, CEO
In plain English, Twist is trying to become the picks-and-shovels provider for a new wave of biologics discovery. If AI models help customers design candidates faster, Twist wants to own more of the design-build-test cycle. That is the strategic narrative management is selling, and this quarter gave it more weight because therapeutics revenue rose 55% YoY.
CFO Adam Laponis handled the financial side of that story. Management raised FY2026 revenue guidance to $442M to $447M and reiterated adjusted EBITDA breakeven by Q4 FY2026. The guidance raise matters because companies do not usually lift the top-line outlook in a shaky demand environment unless order trends support it.
We remain firmly on track to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. — Adam Laponis, CFO
That breakeven target has become the financial anchor for the TWST earnings story. Revenue growth alone is no longer enough for many investors. The market wants proof that growth can convert into a business model with discipline. Gross margin above 50% and a smaller adjusted EBITDA loss helped that case, even if EPS missed.
Analyst Q&A Highlights From the TWST Earnings Call
The most revealing exchanges on the TWST earnings call focused on three areas: how real the AI demand wave is, whether NGS reacceleration can hold, and how much room Twist still has to win share through better sequence acceptance rates.
First, analysts pressed on the quality of the AI-enabled discovery opportunity. Management's answer was that this is not a concept trade. Leproust described several customer workflow models already in use, from large pooled DNA library orders to fully managed discovery programs. She also tied the AWS relationship to active scientific launch partners including Memorial Sloan Kettering Cancer Center.
We identified this emerging category of AI early and invested ahead of the market acceleration with increasing adoption across pharma, drylab and big tech companies. — Emily Leproust, CEO
That response matters because it reframes AI from buzzword to order structure. Management did not just talk about excitement. It described how customers buy, how workflows differ, and where Twist captures value across those workflows.
Second, analysts pushed on NGS, which has been a key debate area for life science tools names. Twist defended the segment by pointing to 12% YoY growth and 9% sequential growth, with particular strength in oncology diagnostics and MRD testing. Management argued that these applications demand high sensitivity, custom panel design, and reliable manufacturing, which plays directly into Twist's platform strengths.
Third, analysts dug into platform expansion and acceptance rates. President and COO Patrick Finn gave one of the more revealing operational comments of the call. He said Twist currently accepts about 97% of clonal genes and can manufacture about 98.5% of them, while broader DNA request acceptance is about 99%. The company is pushing that higher.
More sequences accepted means more orders won and we intend to win them. — Patrick Finn, President and COO
That is an important Q&A takeaway because it shows where management still sees low-drama, high-value execution gains. This is not a flashy metric, but it is commercially meaningful. If a customer has one problematic sequence in a larger order, the whole order can go elsewhere. Raising acceptance rates is a direct way to capture more wallet share.
The Q&A tone also reinforced something the market is still debating: whether Twist is simply growing with the market or actively taking share. Management clearly argued for the second view. Between the 28% growth in DNA synthesis and protein solutions, the therapeutics jump of 55%, and the AWS tie-in, the company made the case that its growth is not just a sector rebound. It is platform-led expansion.
Bottom Line
Twist Bioscience Corporation earnings analysis comes down to a simple trade-off. TWST delivered strong revenue growth, better margins, and higher FY2026 guidance, but the EPS miss kept pressure on the stock and the shares dropped hard.
For investors, the next phase is about whether Twist can turn platform strength into cleaner earnings follow-through. Right now, the business is growing fast enough to keep the bull case alive, but the market is making it clear that growth alone no longer gets a free pass.
+Why did Twist Bioscience stock fall after earnings?
Twist Bioscience (TWST) fell because its quarterly EPS came in at -$0.71, well below the -$0.54 consensus estimate. Investors focused on the larger-than-expected loss even though revenue rose 19.3% year over year to $110.7 million.
+Did Twist Bioscience beat revenue expectations in the latest quarter?
Yes. Twist Bioscience reported revenue of $110.7 million, which was roughly in line with the Street’s $110 million estimate. Revenue also increased 19.3% year over year and marked the company’s 13th straight quarter of sequential growth.
+What was Twist Bioscience’s updated guidance after earnings?
Management raised full-year FY2026 revenue guidance to $442 million to $447 million. The company also reiterated its goal of reaching adjusted EBITDA breakeven in Q4 FY2026.
+Which Twist Bioscience business segments grew the fastest?
DNA synthesis and protein solutions was the fastest-growing segment, rising 28% year over year to $53.3 million. NGS applications also grew, reaching $57.4 million, up 12% year over year and 9% sequentially.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on TWST?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
